Editas Medicine Inc. (EDIT) is a biotechnology company that focuses on the development of genome editing technologies for the treatment of genetic diseases. The company's platform is based on the CRISPR/Cas9 system, which enables precise and efficient editing of DNA sequences. Editas Medicine is developing a pipeline of product candidates for the treatment of various diseases, including inherited retinal diseases, sickle cell disease, and cancer. Its lead product candidate, EDIT-101, is an experimental CRISPR-based therapy for the treatment of Leber congenital amaurosis type 10 (LCA10), a rare genetic eye disease that causes progressive vision loss. The company is headquartered in Cambridge, Massachusetts. As of September 2021, Editas Medicine had a market capitalization of approximately $2.68 billion.
Editas Medicine Inc. (EDIT) is a biotechnology company that focuses on the development of genome editing technologies for the treatment of genetic diseases. The company's platform is based on the CRISPR/Cas9 system, which enables precise and efficient editing of DNA sequences. Editas Medicine is developing a pipeline of product candidates for the treatment of various diseases, including inherited retinal diseases, sickle cell disease, and cancer. Its lead product candidate, EDIT-101, is an experimental CRISPR-based therapy for the treatment of Leber congenital amaurosis type 10 (LCA10), a rare genetic eye disease that causes progressive vision loss. The company is headquartered in Cambridge, Massachusetts. As of September 2021, Editas Medicine had a market capitalization of approximately $2.68 billion.